The Senate Finance Committee today held a hearing on “tackling opioid and substance use disorders in Medicare, Medicaid and human services programs.” Chairman Orrin Hatch (R-UT) said he has already identified several areas of potential bipartisan support, including “the need to evaluate access to and utilization of non-opioid treatment options for managing pain; enhancing data-sharing to promote appropriate health care interventions and strengthen program integrity; and ensuring evidence-based care is available for patients to identify and treat opioid use disorders.” Ranking Member Ron Wyden (D-OR) called Medicaid “a key part of any solution.” He also criticized opioid drug makers and distributors for contributing to the crisis, and said “they need to be brought before this committee and held accountable.” Testifying at the hearing were Assistant Secretary for Health Brett Giroir, M.D., senior advisor to the HHS secretary on mental health and opioid policy, and Kimberly Brandt, principal deputy administrator for operations at the Centers for Medicare & Medicaid Services.

Related News Articles

Headline
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…
Headline
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Headline
As the House Energy and Commerce Committee works to reauthorize key programs within the Substance Use-Disorder Prevention that Promotes Opioid Recovery and…
Headline
While counseling and other services are an important part of a comprehensive treatment plan for opioid use disorder, the provision of medication should not be…
Headline
AHA today launched an updated Opioid Stewardship Hub, featuring the latest tools and resources to help hospitals and health systems address the opioid epidemic…
Headline
The Food and Drug Administration last week required certain labeling updates for opioid pain medicines in an effort to reduce unnecessary prescribing and…